Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 259

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

Zaja, Francesco, Baccarani, Michele, Mazza, Patrizio, Bocchia, Monica, Gugliotta, Luigi, Zaccaria, Alfonso, Vianelli, Nicola, Defina, Marzia, Tieghi, Alessia, Amadori, Sergio, Campagna, Selenia, Ferrara, Felicetto, Angelucci, Emanuele, Usala, Emilio, Cantoni, Silvia, Visani, Giuseppe, Fornaro, Antonella, Rizzi, Rita, De Stefano, Valerio, Casulli, Francesco, Battista, Marta Lisa, Isola, Miriam, Soldano, Franca, Gamba, Enrica, Fanin, Renato · 2010 · Blood

Abstract

Previous observational studies suggest that rituximab may be useful in the treatment of primary immune thrombocytopenia (ITP). This randomized trial investigated rituximab efficacy in previously untreated adult ITP patients with a platelet count of 20 × 109/L or less. One hundred three patients were randomly assigned to receive 40 mg/d dexamethasone for 4 days with or without 375 mg/m2 rituximab weekly for 4 weeks. Patients who were refractory to dexamethasone alone received salvage therapy with dexamethasone plus rituximab. Sustained response (ie, platelet count ≥ 50 × 109/L at month 6 after treatment initiation), evaluable in 101 patients, was greater in patients treated with dexamethasone plus rituximab (n = 49) than in those treated with dexamethasone alone (n = 52; 63% vs 36%, P = .004, 95% confidence interval [95% CI], 0.079-0.455). Patients in the experimental arm showed increased incidences of grade 3 to 4 adverse events (10% vs 2%, P = .082, 95% CI, −0.010 to 0.175), but incidences of serious adverse events were similar in both arms (6% vs 2%, P = .284, 95% CI, −0.035 to 0.119). Dexamethasone plus rituximab was an effective salvage therapy in 56% of patients refractory to dexamethasone. The combination of dexamethasone and rituximab improved platelet counts compared with dexamethasone alone. Thus, combination therapy may represent an effective treatment option before splenectomy. This study is registered at http://clinicaltrials.gov as NCT00770562.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-07-229815

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 259

Metadata

Authors
Zaja, F., Baccarani, M., Mazza, P., Bocchia, M., Gugliotta, L., Zaccaria, A., Vianelli, N., Defina, M., Tieghi, A., Amadori, S., Campagna, S., Ferrara, F., Angelucci, E., Usala, E., Cantoni, S., Visani, G., Fornaro, A., Rizzi, R., De Stefano, V., Casulli, F., Battista, M. L., Isola, M., Soldano, F., Gamba, E., & Fanin, R.
Venue
Blood
Published
2010-04-08
Volume
115
Issue
14
Pages
2755-2762
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2088182580
Cited by
259
References
19
FWCI
15.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. https://app.cochat.ai/papers/10.1182/blood-2009-07-229815
The paper
Zaja, F., Baccarani, M., Mazza, P., Bocchia, M., Gugliotta, L., Zaccaria, A., Vianelli, N., Defina, M., Tieghi, A., Amadori, S., Campagna, S., Ferrara, F., Angelucci, E., Usala, E., Cantoni, S., Visani, G., Fornaro, A., Rizzi, R., De Stefano, V., . . . Fanin, R. (2010). Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. https://doi.org/10.1182/blood-2009-07-229815

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.